AstraZeneca Chinese partner aims to produce 400 million vaccine dose

New Delhi: Conflicts continue in many countries of the world with an epidemic caused by Corona virus infection. In this sequence, many countries have developed the covid-19 vaccine and are helping each other. In this sequence, now the Chinese partner of the vaccine AstraZeneca has claimed that it will develop a dose of 400 million vaccines in a year.

Target of Corona Vaccine Doses:

Let us know that at the end of 2019, the first case of corona virus infection was reported from Wuhan province of China. Now Shenzhen Kangtai Biological Products of China said on Tuesday that it has developed a facility that is capable of developing 40 million doses of Covid-19 vaccine AstraZeneca in a year. It also said that this is double the promise made in 2020.

ALSO READ: Serum Institute Seeks Permission For Another Corona Vaccine ‘Covovax’

The firm of Shenzhen issued a press release. It said, "Kangtai is actively involved in the process of vaccine trials and registration in China. Also, the manufacturing plant is completed and trial production is also started here. The firm has the rights to supply the AZD1222 vaccine, developed by Anglo-Swedish drug manufacturer and Oxford University. The vaccine is expected to be approved by mid-2021, after safety data obtained in the first and second phase trials in China.

ALSO READ: US Administration warns Myanmar Military after arrest of Aung Sang Suu Kyi

Stay tuned with the newstrack to get fastest updates. Click @englishnewstrack to follow us on Facebook and @newstrackmedia to follow on Twitter.